Trace level quantitation of multiple compounds - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Trace level quantitation of multiple compounds

Shimadzu’s LCMS-8050 triple quadrupole LC-MS/MS meets the growing demand for trace-level quantitation in clinical research and other markets. It incorporates proprietary ultrafast technologies as well as a newly developed ion source and collision cell technology. As the flagship model of Shimadzu’s UFMS (Ultra-Fast Mass Spectrometry) product line, the LCMS-8050 features high sensitivity, high data quality and the world’s fastest data acquisition rates.

Delivering attogram-level (10-18 grams) sensitivity and possessing unsurpassed ruggedness, the LCMS-8050 achieves its improved sensitivity through two important technologies:

  • Newly designed Heated ESI source improves desolvation and enhances ionization efficiency with the addition of a heated gas used in combination with the nebulizer gas
  • UFsweeper®III collision cell enhances CID efficiency by optimizing the collision cell pressure.

The world’s fastest data acquisition rates
The newly engineered high voltage power supply enables a maximum scan rate of 30,000 u/sec and a 5 msec polarity switching time, making the LCMS-8050 combined with Nexera UHPLC the ideal platform for laboratory productivity. It is now possible to include 1,000 events with up to 32 channels per event for a maximum of 32,000 MRMs per analysis.

User-friendly Operation and Easy Maintenance

  • Plug-in for the new ion source enables easy changing from ESI to APCI or to dual ionization mode (DUIS)
  • The LabSolutions LCMS Version 5.60 software provides seamless integration of HPLC and MS control. An automated MRM optimization routine allows unattended optimization of multiple compounds.

For more information please visit www.shimadzu.eu

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
25%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
11%
Regulatory compliance
36%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
FindPharma Custom Search

Click here